Filing Details

Accession Number:
0001209191-20-020143
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-18 21:09:23
Reporting Period:
2020-03-16
Accepted Time:
2020-03-18 21:09:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1001233 Sangamo Therapeutics Inc SGMO Biological Products, (No Disgnostic Substances) (2836) 680359556
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1389147 George Stephen Dilly C/O Sangamo Therapeautics, Inc.
7000 Marina Blvd.
Brisbane CA 94005
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-16 15,000 $5.42 20,000 No 4 M Direct
Common Stock Disposition 2020-03-16 15,000 $6.02 5,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right-to-Buy) Disposition 2020-03-16 15,000 $0.00 15,000 $5.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,000 2020-03-30 No 4 M Direct
Footnotes
  1. Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 15, 2019.
  3. The price reported is a weighted average price. The shares were sold at prices ranging from $6.00 to $6.20 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  4. The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant.